iSciencePub Date : 2025-05-11DOI: 10.1016/j.isci.2025.112629
Guoliang Feng , Craig Ross Rindt , Stephen G. Ritchie
{"title":"From diesel to electric: potential of drayage trucks transition in Southern California","authors":"Guoliang Feng , Craig Ross Rindt , Stephen G. Ritchie","doi":"10.1016/j.isci.2025.112629","DOIUrl":"10.1016/j.isci.2025.112629","url":null,"abstract":"<div><div>Battery electric drayage trucks (BEDTs) offer an opportunity to decarbonize the drayage fleets. This article analyzes the potential of BEDTs using data on 1,051 drayage trucks in Southern California. A methodology is developed to evaluate energy and charger requirements across singleton, small, and large fleets. This study assesses the fraction of trucks that can be electrified using battery sizes from 100 to 1000 kWh. Our analysis reveals decreasing uncertainties for fleet electrification with increasing battery size and with offsite charging involved. Combining an 800-kWh battery with both depot and offsite charging using 350 kW chargers, approximately 95% of diesel drayage trucks can be electrified. However, singleton fleets demonstrate the lowest performance and experience substantial improvements through offsite charging. Preferred locations for depot and off-site chargers are identified near the Ports of Long Beach and Los Angeles, and the City of Ontario. These results provide essential guidance for electrifying drayage trucks.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112629"},"PeriodicalIF":4.6,"publicationDate":"2025-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112626
Caitlin B. Dingwall , Yo Sasaki , Amy Strickland , Tong Wu , Daniel W. Summers , A. Joseph Bloom , Aaron DiAntonio , Jeffrey Milbrandt
{"title":"Suppressing phagocyte activation by overexpressing the phosphatidylserine lipase ABHD12 preserves sarmopathic nerves","authors":"Caitlin B. Dingwall , Yo Sasaki , Amy Strickland , Tong Wu , Daniel W. Summers , A. Joseph Bloom , Aaron DiAntonio , Jeffrey Milbrandt","doi":"10.1016/j.isci.2025.112626","DOIUrl":"10.1016/j.isci.2025.112626","url":null,"abstract":"<div><div>Programmed axon degeneration (AxD) is a hallmark of many neurodegenerative diseases. In healthy axons, NMNAT2 inhibits SARM1, the key executioner of AxD, to keep it from depleting NAD+ and triggering axon destruction. AxD was assumed to be governed by axon-intrinsic mechanisms, independent of external factors. However, using a human disease model of neuropathy caused by hypomorphic NMNAT2 mutations resulting in chronic SARM1 activation, we demonstrated that neuronal SARM1 can initiate macrophage-mediated axon elimination long before stressed-but-viable axons would otherwise succumb to intrinsic metabolic failure. Chronic SARM1 activation causes axonal blebbing and disrupts phosphatidylserine (PS), a signaling molecule that promotes axon engulfment by macrophages. Neuronal expression of ABDH12, a PS lipase, reduces macrophage activation, preserves axons, and rescues motor function in this model, suggesting that PS dysregulation is an early SARM1-dependent axonal stress signal. Blocking macrophage-mediated axon elimination could be a promising therapeutic strategy for SARM1-dependent neurological diseases.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112626"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"How to predict effective drug combinations – moving beyond synergy scores","authors":"Lea Eckhart , Kerstin Lenhof , Lutz Herrmann , Lisa-Marie Rolli , Hans-Peter Lenhof","doi":"10.1016/j.isci.2025.112622","DOIUrl":"10.1016/j.isci.2025.112622","url":null,"abstract":"<div><div>To improve our understanding of multi-drug therapies, cancer cell line panels screened with drug combinations are frequently studied using machine learning (ML). ML models trained on such data typically focus on predicting synergy scores that support drug development and repurposing efforts but have limitations when deriving personalized treatment recommendations. To simulate a more realistic personalized treatment scenario, we pioneer ML models that make dose-specific predictions of the relative growth inhibition (instead of synergy scores), and that can be applied to previously unseen cell lines. Our approach is highly flexible: it enables the reconstruction of dose-response curves and matrices, as well as various measures of drug sensitivity (and synergy) from model predictions, which can finally even be used to derive cell line-specific prioritizations of both mono- and combination therapies.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112622"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112614
Bo Fang , Kai Wang , Yinghui Li , Bo Li , Xinzhe Chen , Kun Wang , Sumin Yang
{"title":"Understanding tsRNAs: From classification to disease mechanisms","authors":"Bo Fang , Kai Wang , Yinghui Li , Bo Li , Xinzhe Chen , Kun Wang , Sumin Yang","doi":"10.1016/j.isci.2025.112614","DOIUrl":"10.1016/j.isci.2025.112614","url":null,"abstract":"<div><div>tRNA-derived small RNAs (tsRNAs) are a class of non-coding RNA molecules generated through the cleavage of tRNA, primarily categorized into tRNA-derived fragments (tRFs) and tRNA-derived stress-induced small RNAs (tiRNAs). tsRNAs have been shown to play diverse roles in essential biological processes, such as gene expression regulation, cellular stress response, proliferation, and differentiation. Furthermore, tsRNAs are abnormally expressed in various disease states and play a key role in disease pathogenesis. This article reviews the generation, classification, and nomenclature of tsRNAs, examines their potential biological functions and mechanisms in diseases, and discusses their promise as biomarkers and therapeutic targets. Although tsRNA research is still in its early stages, the potential applications of tsRNAs in disease treatment are promising and warrant further investigation.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112614"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144137986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112620
Jiayi Ma , Yaohui Wang , Ziping Wu , Liheng Zhou , Yanping Lin , Shuguang Xu , Jie Zhang , Jingsong Lu , Wenjin Yin
{"title":"RBC balanced immuno-inflammatory signatures identify advanced breast cancer patients on CDK4/6 inhibitors at increased risk of progression and death","authors":"Jiayi Ma , Yaohui Wang , Ziping Wu , Liheng Zhou , Yanping Lin , Shuguang Xu , Jie Zhang , Jingsong Lu , Wenjin Yin","doi":"10.1016/j.isci.2025.112620","DOIUrl":"10.1016/j.isci.2025.112620","url":null,"abstract":"<div><div>The association of immuno-inflammatory parameters, especially RBC balanced signatures, with survival outcomes and adverse events still require investigation for advanced breast cancer (ABC) patients receiving cyclin-dependent kinase 4/6 inhibitor (CDKI). Herein, RBC balanced immuno-inflammatory (RBC-IMM) score was developed and capable of predicting progression-free survival (PFS) events (<em>p</em> < 0.001), death (<em>p</em> < 0.001) and grade 3/4 leukopenia (<em>p</em> = 0.010). RBC-IMM score also predicted PFS more accurately than classical-IMM score (AUC = 0.766 and 0.596 respectively, <em>p</em> = 0.005). Besides, clinico+RBC_index exhibited superior performance to clinico_index for 18-month PFS through machine learning (training set: AUC = 0.830 and 0.764 respectively; testing set: AUC = 0.894 and 0.715 respectively). Additionally, liquid chromatography-tandem mass spectrometry identified phosphatidylcholine notably involved in RBC-CDKI interaction, contributing to the construction of clinico+PtdCho_index with better PFS prediction than clinico_index (AUC = 0.854 and 0.733 respectively). These findings indicate that RBC-IMM related parameters have the advantage of identifying benefit and safety in CDKI-treated ABC patients over classical indicators.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112620"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112615
Yifei Zhang , Keyu Yin , Runsheng Ma , Yuxiao Sun , Longlong Wang , Detao Yin
{"title":"Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications","authors":"Yifei Zhang , Keyu Yin , Runsheng Ma , Yuxiao Sun , Longlong Wang , Detao Yin","doi":"10.1016/j.isci.2025.112615","DOIUrl":"10.1016/j.isci.2025.112615","url":null,"abstract":"<div><div>Immune checkpoint therapy targeting PD-L1/PD-1 represents a key cancer treatment strategy. PD-L1 binds PD-1 on T cells, suppressing activation and enabling tumor immune escape. Although the blockade of the PD-L1/PD-1 pathway has demonstrated significant anti-tumor effects, the overall response rate remains suboptimal in solid tumors. Therefore, understanding the molecular mechanisms underlying PD-L1 deregulation is essential for enhancing the efficacy of PD-L1/PD-1 blockade therapies. As our comprehension of the regulatory mechanisms governing the PD-L1/PD-1 pathway continues to evolve, ongoing exploration of new immunotherapy targets remains critical. This article provides a comprehensive review of recent research concerning the regulation of PD-L1 expression. It encompasses aspects such as its structural characteristics, genomic alterations and rearrangements, epigenetic modifications, inflammatory signaling pathways, oncogenic signaling pathways, microRNA regulation, and post-translational modifications. Additionally, this article illustrates notable advancements and limitations regarding the application of PD-L1 as an immunotherapeutic target in current clinical settings.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112615"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112623
Tadamoto Isogai , Kevin M. Dean , Philippe Roudot , Evgenia V. Azarova , Kushal Bhatt , Meghan K. Driscoll , Shaina P. Royer , Nikhil Mittal , Bo-Jui Chang , Sangyoon J. Han , Reto Fiolka , Gaudenz Danuser
{"title":"Direct Arp2/3-vinculin binding is required for pseudopod extension, but only on compliant substrates and in 3D","authors":"Tadamoto Isogai , Kevin M. Dean , Philippe Roudot , Evgenia V. Azarova , Kushal Bhatt , Meghan K. Driscoll , Shaina P. Royer , Nikhil Mittal , Bo-Jui Chang , Sangyoon J. Han , Reto Fiolka , Gaudenz Danuser","doi":"10.1016/j.isci.2025.112623","DOIUrl":"10.1016/j.isci.2025.112623","url":null,"abstract":"<div><div>A critical step in cell morphogenesis is the extension of actin-dense pseudopods, controlled by actin-binding proteins (ABPs). While this process is well-understood on glass coverslips, it is less so in compliant three-dimensional environments. Here, we knocked out a series of ABPs in osteosarcoma cells and evaluated their effect on pseudopod extension on glass surfaces (2D) and in collagen gels (3D). Cells lacking the longest Arp3 gene variant, or with attenuated Arp2/3 activity, had the strongest reduction in pseudopod formation between 2D and 3D. This was largely due to reduced activity of the hybrid Arp2/3-vinculin complex, which was dispensable on glass. Our data suggests that concurrent formation of actin branches <em>and</em> nascent adhesions, supported by Arp2/3-vinculin interactions, is essential to form mechanically stable links between fibrous extracellular matrix and actin in 3D. This highlights how experiments on stiff, planar substrates may conceal actin architectural features that are essential for morphogenesis in 3D.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112623"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112618
Florian Meyer , Cristiana Lungu , Bettina Noll , David Benz , Felix Fränkle , Miguel Â. Ferreira , Raluca Tamas , Monilola A. Olayioye
{"title":"Reciprocal regulation of Solo and Src orchestrates Src trafficking to promote mesenchymal cell migration","authors":"Florian Meyer , Cristiana Lungu , Bettina Noll , David Benz , Felix Fränkle , Miguel Â. Ferreira , Raluca Tamas , Monilola A. Olayioye","doi":"10.1016/j.isci.2025.112618","DOIUrl":"10.1016/j.isci.2025.112618","url":null,"abstract":"<div><div>Rho GTPases are key regulators of cell motility and membrane trafficking, influencing critical processes such as epithelial-mesenchymal transition (EMT). Among them, the small GTPase RhoB plays a pivotal role, but the mechanisms underlying its regulation remain largely unclear. We have previously identified the Rho guanine nucleotide exchange factor (RhoGEF) Solo (ARHGEF40) as a regulator of endosomal RhoB in epithelial cells. Here, we find that Solo is upregulated in breast cancer cells with high EMT scores and promotes cell motility through its RhoGEF activity. Solo’s ability to enhance migration is further regulated by phosphorylation at tyrosine 242, mediated by the proto-oncogene Src. By combining high-resolution imaging with photoconversion assays, we further demonstrate that Solo regulates Src trafficking dynamics, localization, and consequently signaling at focal adhesions. Together, our data identify Solo as a novel feedback regulator of Src and a key driver of the motility of breast cancer cells with mesenchymal characteristics.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112618"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144123679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
iSciencePub Date : 2025-05-09DOI: 10.1016/j.isci.2025.112625
Yu Zhang , Christopher D. Kontos , Brian H. Annex , Aleksander S. Popel
{"title":"Promoting vascular stability through Src inhibition and Tie2 activation: A model-based analysis","authors":"Yu Zhang , Christopher D. Kontos , Brian H. Annex , Aleksander S. Popel","doi":"10.1016/j.isci.2025.112625","DOIUrl":"10.1016/j.isci.2025.112625","url":null,"abstract":"<div><div>Dysregulated angiogenesis signaling leads to pathological vascular growth and leakage, and is a hallmark of many diseases including cancer and ocular diseases. In peripheral arterial disease, the concomitant increase in vascular permeability presents significant challenges in therapeutic efforts to improve perfusion by stimulating vascular growth. Building a mechanistic understanding of the endothelial control of vascular growth and permeability signaling is crucial to guide our efforts to identify therapeutic strategies that permit blood vessel growth while maintaining vascular stability. We develop a mechanistic systems biology model of the endothelial signaling network formed by the vascular endothelial growth factor (VEGF) and angiopoietin (Ang)-Tie pathways, two major signaling pathways regulating vascular growth and stability. Our model, calibrated and validated against experimental data, reveals the mechanisms through which chronic Ang1 stimulation protects endothelial cells from VEGF-induced hyperpermeability, and predicts that combining Src inhibition with Tie2 activation can inhibit vascular leakage without disturbing angiogenesis signaling.</div></div>","PeriodicalId":342,"journal":{"name":"iScience","volume":"28 6","pages":"Article 112625"},"PeriodicalIF":4.6,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144107631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}